Advanced search
Publication Cover
Patient Preference and Adherence Volume 10, 2016 - Issue
Submit an article Journal homepage
100
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting

Rishma Gohil1 National Institute for Health Research Moorfields Biomedical Research Centre, London, UK;2 Diabetes Nursing, King’s College London, London, UK
,
Roxanne Crosby-Nwaobi1 National Institute for Health Research Moorfields Biomedical Research Centre, London, UK;2 Diabetes Nursing, King’s College London, London, UK
,
Angus Forbes2 Diabetes Nursing, King’s College London, London, UK
,
Ben J Burton3 Ophthalmology Department, James Paget University Hospital, Great Yarmouth, UK
,
Philip Hykin1 National Institute for Health Research Moorfields Biomedical Research Centre, London, UK
&
Sobha Sivaprasad1 National Institute for Health Research Moorfields Biomedical Research Centre, London, UK;4 Laser and Retinal Research Unit, King’s College Hospital, London, UKCorrespondence[email protected]
Pages 949-955 | Published online: 26 May 2016

References

  • FineSLBergerJWMaguireMGHoACAge-related macular degenerationN Engl J Med2000342748349210675430
  • EvansJRSmeethLFletcherAERisk of admission to a nursing home among older people with visual impairment in Great BritainArch Ophthalmol2008126101428143318852422
  • FreemanEEEglestonBLWestSKBandeen-RocheKRubinGVisual acuity change and mortality in older adultsInvest Ophthalmol Vis Sci200546114040404516249478
  • BuysLRobertoKAMillerEBliesznerRPrevalence and predictors of depressive symptoms among rural older Australians and AmericansAust J Rural Health2008161333918186720
  • WangJJMitchellPSmithWLeederSRFactors associated with use of community support services in an older Australian populationAust N Z J Public Health199923214715310330728
  • ChakravarthyUHardingSPRogersCAIVAN study investigatorsAlternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trialLancet201338299001258126723870813
  • MaguireMGYingGSCATT Research GroupMartinDFRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
  • Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
  • HolzFGTadayoniRBeattySMulti-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationBr J Ophthalmol201599222022625193672
  • Writing Committee for the UK Age-Related Macular Degeneration EMR Users GroupThe neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuityOphthalmology201412151092110124461586
  • DarziAHigh Quality Care for all: NHS Next Stage Review Final ReportLondonDepartment of Health2008
  • MitchellJBroseLSBradleyCDesign of a measure of satisfaction with treatment for macular degeneration (MacTSQ)Qual Life Res2007A-1202
  • BroseLSBradleyCPsychometric development of the Retinopathy Treatment Satisfaction Questionnaire (RetTSQ)Psychol Health Med200914674075420183546
  • GohilRCrosby-NwaobiRForbesABurtonBHykinPSivaprasadSCaregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degenerationPLoS One2015106e012936126056840
  • Macular degeneration (age-related) – ranibizumab and pegaptanib [TA155]LondonNICE Available from: www.nice.orgAccessed April 18, 2016
  • WoodcockAPlowrightRKennedy-MartinTHirschAffytcheTBradleyCDevelopment of the new Retinopathy Treatment Satisfaction Questionnaire (RetTSQ)Proceedings of Vision 2005; International Congress Series20051282342346
  • LarsenDLAttkissonCCHargreavesWANguyenTDAssessment of client/patient satisfaction: development of a general scaleEval Program Plann1979219720710245370
  • MaldeSDowsonCFraserOPatient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladderBJU Int2015116344344925523401
  • MangioneCMLeePPGutierrezPRSpritzerKBerrySHaysRDNational Eye Institute Visual Function Questionnaire Field Test InvestigatorsDevelopment of the 25-item National Eye Institute Visual Function QuestionnaireArch Ophthalmol200111971050105811448327
  • MitchellJWolffsohnJSWoodcockAPsychometric evaluation of the MacDQoL individualised measures of the impact of macular degeneration on quality of lifeHealth Qual Life Outcomes200532515831093
  • Brooks R EuroQolThe current state of playHealth Policy199637537210158943
  • AmoakuWMGaleRPLoteryAJSatisfaction and well-being in patients with myopic choroidal neovascularization treated with ranibizumab in the REPAIR studyPLoS One2015106e012840326039355
  • AuCPFardellNWilliamsMFraser-BellSCampainAGilliesMPatient experiences in retinal trials: a cross-sectional studyBMC Ophthalmol2015158026202164
  • van AstenFEvers-BirkenkampKUvan Lith-VerhoevenJJA prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degenerationActa Ophthalmol201593212613325488348
  • FingerRPHoffmannAEFenwickEKPatients’ preferences in treatment for neovascular age-related macular degeneration in clinical routineBr J Ophthalmol20127997100222535331

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.